Drug-mediated shortening of action potentials in LQTS2 human induced pluripotent stem cell-derived cardiomyocytes by Duncan, Gary et al.
Drug-Mediated Shortening of Action Potentials
in LQTS2 Human Induced Pluripotent Stem
Cell-Derived Cardiomyocytes
Gary Duncan,1 Karl Firth,1 Vinoj George,1,2 Minh Duc Hoang,1,2 Andrew Staniforth,3
Godfrey Smith,4 and Chris Denning1
Cardiomyocytes (CMs) derived from human induced pluripotent stem cells (hiPSCs) are now a well-established
modality for modeling genetic disorders of the heart. This is especially so for long QT syndrome (LQTS), which is
caused by perturbation of ion channel function, and can lead to fainting, malignant arrhythmias and sudden cardiac
death. LQTS2 is caused by mutations in KCNH2, a gene whose protein product contributes to IKr (also known as
HERG), which is the predominant repolarizing potassium current in CMs. b-blockers are the mainstay treatment for
patients with LQTS, functioning by reducing heart rate and arrhythmogenesis. However, they are not effective in
around a quarter of LQTS2 patients, in part, because they do not correct the defining feature of the condition, which
is excessively prolonged QT interval. Since new therapeutics are needed, in this report, we biopsied skin fibroblasts
from a patient who was both genetically and clinically diagnosed with LQTS2. By producing LQTS-hiPSC-CMs,
we assessed the impact of different drugs on action potential duration (APD), which is used as an in vitro surrogate
for QT interval. Not surprisingly, the patient’s own b-blocker medication, propranolol, had a marginal effect on
APD in the LQTS-hiPSC-CMs. However, APD could be significantly reduced by up to 19% with compounds that
enhanced the IKr current by direct channel binding or by indirect mediation through the PPARd/protein 14-3-3
epsilon/HERG pathway. Drug-induced enhancement of an alternative potassium current, IKATP, also reduced APD
by up to 21%. This study demonstrates the utility of LQTS-hiPSC-CMs in evaluating whether drugs can shorten
APD and, importantly, shows that PPARd agonists may form a new class of therapeutics for this condition.
Keywords: human induced pluripotent stem cells, cardiomyocytes, long QT syndrome, electrophysiology,
HERG, PPAR delta
Introduction
Long QT Syndrome (LQTS) is a genetic heart abnormalitycharacterized by extended duration of the QT interval on an
electrocardiogram. A corrected QT (QTc) that exceeds 450ms
in males and 460ms in females is considered prolonged [1].
Symptoms of LQTS can include a repeated history of fainting
and Torsade-de-Pointes, a form of polymorphic ventricular
tachycardia that can lead to ventricular fibrillation and sudden
cardiac death [2]. Early diagnosis of LQTS by clinical and/or
genetic evaluation is important because the first presentation
may be life threatening [3]. Sudden infant death syndrome af-
fects 1 in 2,000 births, of which 12% are thought to be caused by
underlying LQTS [4,5]. Moreover, there is a 21%mortality rate
for symptomatic patients who remain untreated for 1 year [4].
Thirteen subtypes of LQTS have been identified, with the
most prevalent forms being LQTS1, 2, and 3 [3,4]. LQTS2
accounts for *35% to 40% of LQTS cases and the under-
lying cause is mutation of the KCNH2 gene. This encodes
the a-subunit of the rapid-acting inward rectifying potas-
sium IKr current (also known as HERG or Human Ether-a-
go-go-related Gene) and drives rapid repolarization during
the cardiac cycle [4]. Diagnosis is often followed by pre-
scription of b-blockers, such as propranolol and nadolol, as
the first line of treatment [6]. This approach has proven
effective for LQTS1 patients, reducing mortality rate to
0.5%. However, b-blockers may be ineffective in up to 23%
of LQTS2 cases [7,8]. These drugs block the proarrhythmic
effects of circulating adrenergic agonists and the sympa-
thetic nervous system to cause a slowing in heart rate.
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Paradoxically, however, a slower heart rate can be associ-
ated with prolonged QT interval. In LQTS patients, where
QT interval is already long, patients may need to receive an
atrial pacemaker to elevate rate back to normal levels.
Therefore, b-blockers do not treat, and can exacerbate, the
underlying condition of excessively long QT interval and
low rate of cardiac repolarization.
Human induced pluripotent stem cells (hiPSCs), produced
by epigenetic reprogramming of somatic cells, can be differ-
entiated into cardiomyocytes (CMs) at high efficiency, which
has provided a renewable method to create ‘‘patient in a dish’’
models of genetic disease. For channel-based disorders, this in-
cludes LQTS types 1 [9], 2 [10], 3 [11], and 8 [12,13], as well as
LQTS3/Brugada overlap [13] and catecholaminergic polymor-
phic ventricular tachycardia [14]. The LQTS models have been
used to demonstrate that approved and experimental drugs can
be effective in reducing the action potential duration (APD) and
arrhythmic events in hiPSC-CMs, suggesting further extension
of these studies is warranted. To this end, we sought to evaluate
the impact of a panel of seven drugs, including b-blockers, Ikatp
and Ikr modulators, and for the first time PPARd agonists, on
APD and repolarization rates in LQTS2-hiPSC-CMs.
Materials and Methods
All culture was at 37C, 5% CO2 in a humidified envi-
ronment. All reagents for hiPSC production and culture were
from ThermoFisher unless specified.
Generating hiPSCs
Skin fibroblasts were derived under ethical consent, as pre-
viously described [10]. Reprogramming to hiPSCs was done
using the CytoTune 2.0 nonintegrating Sendai virus. In brief,
on d0, one well of a six-well plate was seeded with 2·105 cells
in a fibroblast medium (DMEM supplemented with 10% fetal
calf serum, 1% nonessential amino acids, 1% glutamine, and
100mM b-mercaptoethanol). On d1, CytoTune 2.0 was added
to 3mL of fibroblast medium to give an MOI of 5:5:3 and this
was used to replace the medium on the cells. From d2 to*d5,
the fibroblast medium was changed daily until the cells reached
*80% confluence. On d5, the cells were passaged using
0.05% trypsin and split at a ratio of 1:3 into 3·35mm dishes
coasted in vitronectin peptide and cultured in E6 medium
supplemented with 100ng/mL of basic fibroblast growth factor
(FGF2; PeproTech). The medium was changed daily until the
emergence of definitive hiPSC colonies by *d12, at which
point the medium was changed to E8 medium. E8 medium was
changed daily until *d21 when individual colonies were iso-
lated by mechanical dissociation using a stem cell cutting tool
(14601; 0.190–0.210mm; Vitrolife) and seeded into 48-well
plates coated in Matrigel for expansion in E8 medium.
Confirming pluripotent phenotype
Transcription factors associated with pluripotency were as-
sessed in hiPSCs bywashing phosphate-buffered saline and then
fixing in 4% paraformaldehyde for 15min at room temperature.
Permeabilization was with 0.1% Triton X-100 for 10min.
The primary antibodies used were anti-OCT4 (1:50, mouse,
SC-5279; Santa Cruz), anti-SOX2 (1:200, goat, AF2018;
R&D Systems) and anti-NANOG (1:200, goat, AF1997;
R&D Systems), with reactions carried out overnight at 4C.
Alexa-488 conjugated secondary antibodies were used, either
as anti-mouse (1:1,000, A32723; Invitrogen) or anti-goat
(1:1,000, A11055; Invitrogen), as appropriate, with reactions
for 1 h at room temperature on a shaker. Cells were visualized
using an Operetta confocal plate reader (PerkinElmer). Flow
cytometry was also used to assess surface markers associated
with pluripotency. Cells were fixed in 4%paraformaldehyde in
suspension for 15min at room temperature. Cells were then
centrifuged for 5min at 160 g. The pellet was then washed in
phosphate-buffered saline once before being centrifuged at 160
g again. The cell pellet was then resuspended and stained for
TRA-1-81 (mouse, 1:100, 12-8883-82; eBioscience), SSEA4
(mouse, 1:100, 12-8843-42; eBioscience), and SSEA1 (mouse,
1:100, 12-8813-42; eBioscience). Flow cytometry was per-
formed on MoFlo (Beckman Coulter).
Differentiation of hiPSC-CMs
Human iPSCs were seeded at 9 · 104/cm2 and allowed to
reach >90% confluence (approximately by d3) with daily
changes in E8 medium. The medium was then changed to
StemPro34 supplemented with 1 ng/mL BMP4. Next day, the
medium was changed to fresh StemPro34 supplemented with
5 ng/mL BMP4 and 8 ng/mL Activin A for 48 h. The medium
was then changed to RPMIB27 (minus insulin) supplemented
with 10 nM KY02111 and XAV939, and then incubated for
48 h. The medium was then changed to RPMI B27 supple-
mented with 10 nMKY02111 andXAV939 and incubated for
48 h. After this time, cells were cultured routinely in RPMI
B27 with medium changes every 2–3 days.
Assessment of electrophysiology
The CellOPTIQ platform [15] was used to record optical-
based action potentials fromhiPSC-CMs.Cells were seeded into
Matrigel-coated 96-well plates at a density of 50,000 cells per
well. These hiPSC-CMs were then incubated at 37C and 5%
CO2 for 48h to allow cells to recover. To image the voltage
properties of the hiPSC-CMs, they were dyed using FluoVolt
(F10488). Media were removed from wells and serum-free
media (SFM) (DMEM +0.5M galactose (Sigma-Aldrich) and
100mM sodium pyruvate) containing FluoVolt (PartA: 0.5mL/
mL and PartB: 5mL/mL)were added; these cells were incubated
at 37Cand5%CO2 for 30min.After the 30-min incubation, the
medium was removed and the hiPSC-CMs washed once with
SFM before 100mL of fresh SFM was added to wells. These
plates were then incubated at 37C and 5% CO2 for 15min to
allow the hiPSC-CMs to equilibrate before recording traces.
For drug treatment, a basal recording was taken before
20 mL of drug was added to the well; all drugs were dissolved
in dimethyl sulfoxide (DMSO) and added to the cells with a
0.1% DMSO concentration. After this addition, the hiPSC-
CMs were incubated at 37C and 5% CO2 for 30min before a
second measurement was taken. The drugs used in the study
were all purchased from Sigma: Telmisartan (Cat: T8949);
GW0742, (Cat: G3295); NS1643 (Cat: N0663); Ginsenoside
RG3 (Cat: SML0184); Minoxidil (Cat: M4145); and Nicor-
andil (Cat N3539).
Voltage data were analyzed using CellOPTIQ proprietary
software of Clyde Biosciences and were normalized to a
maximum amplitude of 1 and minimum of 0 to standardize
height for comparison of traces created in Origin software
package.
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Results
Derivation and characterization
of LQTS2-hiPSC-CMs
Skin fibroblastswere derived under informedconsent froma
19-year-old LQTS2 patient when she received a preventative
implantable cardioverter defibrillator, as previously described
[10]. Clinically, the patient had experienced polymorphic
ventricular tachyarrhythmia at rates of 230 bpm and had a QTc
of up to 571ms on the electrocardiogram (Fig. 1A). Geno-
typing showed an LQTS2-associated autosomal dominant
point mutation c.G1681A (p.A561T) in KCNH2.
Following integration-free reprogramming of the skin fi-
broblasts with recombinant OCT4, SOX2, cMYC, and KLF4
Sendai viruses, single colonies of LQTS2-hiPSCs were picked
and expanded in E8 culture medium on Matrigel. Immuno-
staining and image analysis showed that nearly all cells ex-
pressed the transcription factors, OCT4, SOX2, and NANOG
(Fig. 1B). This was cross-confirmed by positive staining by
flow cytometry to the surface markers, TRA1-81 and SSEA4,
but not the differentiation marker, SSEA1 (Fig. 1C). Cultures
were routinely passaged at a ratio of 1:8 (*20,000 cells/cm2)
and harvested 3 days later, equating to a population doubling
rate of*24–27 h, which is consistent with the wider literature
[16]. Karyotyping of 30 metaphase spreads and assembly of
homologous chromosomes into a karyogram showed no ab-
normalities (Fig. 1D). Genotyping of the LQTS2-hiPSC line
confirmed the c.G1681A mutation (Fig. 1E). Directed mono-
layer differentiation protocol produced beating sheets of CMs
that were >80% positive for a-actinin staining (Fig. 1F).
To examine electrophysiology characteristics, confluent
monolayers of LQTS-hiPSC-CMs were established in 96-well
plates and loaded with the voltage-sensitive dye, FluoVolt.
Optical traces were recorded and analyzed using the CellOPTIQ
platform, as previously described [17]. For comparison, hiPSC-
CMs were also produced from skin fibroblasts donated by the
LQTS2 patient’s father, who was considered healthy with no
G1681A mutation, no electrical anomalies in heart function
(electrocardiogram QTc of 455ms), and no clinical symptoms.
Averaged traces (Fig. 1G) confirmed significantly prolonged
APDs in LQTS2-hiPSC-CMs relative to hiPSC-CMs from the
healthy father, with respective values for APD50 of 374–25ms
versus 348–47ms, APD90 of 443–31ms versus 404–42ms,
and triangularization (APD90 - APD30) of 158–15ms versus
120–12ms (Fig. 1G; all P<0.05 by unpaired t-test).
Since the LQTS2 patient’s treatment includes b-blockers,
such as the nonspecific b1- and b2-adrenoceptor antagonist,
propranolol, we wished to evaluate the effect of this drug on
action potential characteristics of the corresponding LQTS-
hiPSC-CMs. Using the same voltage-sensitive dye as above,
baseline action potentials were recorded for 30min before
adding propranolol at 5·½ log concentration increases from
10 to 1,000 nM, an approach also adopted for all subsequent
drug tests. For propranolol, calculation of percentage change in
APD50, APD90, and triangularization showedmarginal change
only, occasionally bordering on significance (Fig. 1H).
Effect of IKr modulators on the action potential
of LQTS2-hiPSC-CMs
We have previously shown that the G1681A mutation in
KCNH2 disrupts trafficking of the IKr/HERG channel to the
cell membrane [18]. The channel comprises a tetrameric
complex and the mutation is autosomal dominant negative.
This means that even when the healthy and mutant KCNH2
alleles are expressed at equal 1:1 ratios, only 6% of IKr
channels are functional because one or more mutant proteins
in the tetrameric complex compromises channel function
[18]. This explains why LQTS2 is associated with such
dramatic increases in QT interval. Therefore, we wished to
evaluate whether different drugs could reduce the APD in
LQTS-hiPSC-CMs.
Because IKr is still at least partially active in LQTS2-
hiPSC-CMs with the G1681A mutation, we first evaluated
whether chemicals that interact directly with this channel
could shorten APD. Ginsenoside RG3 is known to modulate
IKr by interacting with a Ser631 residue the channel pore
entryway, which decelerates channel deactivation [19]. A
second compound, NS1643, changes the voltage dependence
of inactivation, which has previously led to an increase in
steady state and tail currents in Xenopus laevis oocytes en-
gineered to overexpress the HERG channel [20]. As before, a
½ log range from 10 to 1,000 nM was used in combination
with the CellOPTIQ to measure optical recordings from
LQTS2-hiPSC-CMs loadedwith FluoVolt (Fig. 2). The effect
of Ginsenoside RG3 was relatively modest on APD, with
significant reductions reached at ‡100 nM and only then
equating to around an 8% reduction in APD90 and triangu-
larization (Fig. 2A, Bi). In contrast, at multiple concentra-
tions, NS1643 caused highly significant reductions in all
three parameters, APD50, APD90, and triangularization, with
the maximum concentration leading to a reduction of nearly
20%. A change in the action potential morphology was also
seen, as indicated by significant reduction in triangularization
(Fig. 2A, Bii).
We wished to determine whether alternative methods of
enhancing IKr may be beneficial to the action potential
characteristics of LQTS-hiPSC-CMs. It has been reported
that the PPARd pathway targets protein 14-3-3 epsilon,
which in turn interacts with HERG to stabilize the PKA-
phosphorylated state of the channel by shielding phosphates
from degradation [21]. Therefore, we selected two PPARd
agonists, Telmisartan and GW0742 [22,23], using them
across the same concentration ranges described above
(Fig. 3). Overall, the observed effect on APD50, APD90, and
triangularization of LQTS2-hiPSC-CMs treated with Telmi-
sartan and GW0742 was similar to that seen for NS1643.
Thus, reduction inAPD50 andAPD90was highly significant at
many of the concentrations used (Fig. 3). The impact of
GW0742 was particularly dramatic, with the maximum
concentration tested causing a reduction of *20% for both
APD50 and APD90, and*14% for triangularization (Fig. 3).
Effect of IKATP modulators on the action potential
of LQTS2-hiPSC-CMs
Finally, we sought to evaluate whether modulation of
other potassium currents, including IKATP, would be bene-
ficial to the action potential characteristics of LQTS CMs.
Nicorandil has dual properties in that it activates potassium
channels to enhance efflux and has hyperpolarizing effects
by inhibiting voltage-gated calcium channels [24]. The sul-
fated form of Minoxidil causes relaxation of vascular
smooth muscle by opening IKATP channels [25]. Overall, the
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observed effect on APD50 and APD90 of LQTS2-hiPSC-
CMs of Minoxidil and Nicorandil was similar to that seen
for NS1643, Telmisartan, and GW0742. Highly significant
reduction in these parameters was seen through the con-
centration ranges, with the highest concentration causing a
reduction of up to 19% (Fig. 4). While the impact on tri-
angularization was less pronounced, significant reductions
were seen for Minoxidil, particularly at higher concentra-
tions (Fig. 4).
Discussion
We seized the opportunity to harvest skin cells from an
LQTS2 patient undergoing surgery to receive preventa-
tive implantable cardioverter defibrillator. Integration-free
hiPSCs were produced and the derived CMs were used to
evaluate impact of drugs on APD as an in vitro surrogate
measurement of QT interval. While the b-blocker, pro-
pranolol, failed to meaningfully reduce APD in LQTS-
hiPSC-CMs, direct or indirect interaction of compounds
with IKr and IKATP channel was able to induce reductions of
up to 21%. The use of indirect activation of IKr by modu-
lation of the PPARd pathway was of particular importance
as it highlights a new potential route for therapeutic inter-
vention of LQTS2, which should be explored further in the
future.
A feature often highlighted with regard to recombinant
Sendai virus reprogramming is that it is integration free
and viral-derived transcripts are readily diluted within the
first few passages after hiPSC lines are established. Con-
trary to this notion, our routine checks for persistence of
transgene expression by reverse transcription polymerase
chain reaction at passages*15 after hiPSC derivation were
positive for cMYC. Indeed, when we surveyed eight of
the hiPSC lines in our laboratory produced using the Cy-
toTune2.0 recombinant Sendai virus system, expression
analysis showed 50% and 12.5% were positive for cMYC
and KLF4, respectively, although none was positive for
polycistronic KLF4–OCT3/4–SOX2. Nevertheless, residual
transgene expression did not impact pluripotency marker
expression, stable karyotype, or high efficiency-directed
monolayer differentiation into functional CMs, with values
FIG. 2. Direct modulation of IKr channels. LQTS2-hiPSC-CMs were treated with the plant constituent, Ginsenoside RG3,
or the synthetic compound, NS1643. After loading with the voltage-sensitive dye, FluoVolt, optical recordings were made
using the CellOPTIQ platform. Averaged traces across the concentration range are shown in (A), while the derived
percentage changes in APD50, APD90, and triangularization are shown in (Bi; RG3) and (Bii; NS1643). Data are mean –
SEM with 40 replicates for BL (0) and 8 replicates for all other treatments; Dunnett’s test comparison to baseline (BL [0]);
*P £ 0.05; **P £ 0.01; ***P £ 0.001; ****P£ 0.0001. Color images available online at www.liebertpub.com/scd
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for each matching best in class published elsewhere in the
literature [26,27]. This provided an opportunity to use the
LQTS-hiPSC-CMs to evaluate the impact of drugs on APD,
which is an in vitro surrogate for QT interval on the elec-
trocardiogram.
Although b-blocker therapy is highly efficacious and suc-
cessful for most LQTS1 patients, it is often insufficient as a
standalone treatment for LQTS2, where up to 23% of patients
continue to experience cardiac events [7]. This notion was
supported by our data with propranolol, which showed a
marginal effect on APD in LQTS-hiPSC-CMs. This result
was expected because propranolol is a nonspecific b1- and
b2-adrenoceptor inhibitor that works by competitive binding
to outcompete chronotropic agents, such as isoprenaline
[28,29]. However, the underlying cause of altered CM func-
tion in LQTS2 is not beat rate, but rather excessively long QT
interval, which is not treated with b-blockers.
It is not surprising that nearly half of the genotyped cases
for LQTS are due to mutations in KCNH2. The IKr/HERG
channel is the major driving force behind phase 3 repolar-
ization during the cardiac action potential [30]. Furthermore,
the IKr channel is formed from a tetrameric complex, and its
ability to be trafficked to the cell membrane and/or flux
potassium ions is compromised if one or more of the four
proteins is mutated [31]. It is for this reason that even when
expression ratios of healthy and mutant alleles of KCNH2
are equal at 50% each, only 6% of ion channels are pre-
dicted to be functional [18]. This makes it all the more
important to find methods that amplify the activity of the
remaining functional channels.
For each of the drugs we used to modulate ion channel
function, a 5 ·½ log concentration range was used. While
some drugs have previously been used on CMs in culture
(eg, Nicorandil [10] and NS1643 [32]), several others had
not been, and we relied on ranges that spanned published
concentrations, including those used in cancer cell lines,
neuronal cultures, and human mesangial cells [33–35]. Ni-
corandil has previously been shown to be effective in re-
ducing APD by 19% in integrating lentivirally derived
LQTS-hiPSC-CMs, as measured from action potentials
FIG. 3. Indirect modulation of IKr channels with PPARd agonists. LQTS2-hiPSC-CMs were treated with the PPARd
agonists, GW0742, and Telmisartan, which are thought to stabilize the PKA-phosphorylated state of HERG by protein 14-3-
3 epsilon. After loading with the voltage-sensitive dye, FluoVolt, optical recordings were made using the CellOPTIQ
platform. Averaged traces across the concentration range are shown in (A), while the derived percentage changes in APD50,
APD90, and triangularization are shown in (Bi; GW0742) and (Bii; Telmisartan). Data are mean –SEM with 40 replicates
for BL (0) and 8 replicates for all other treatments; Dunnett’s test comparison to baseline (BL [0]); *P £ 0.05; **P £ 0.01;
***P£ 0.001; ****P£ 0.0001. Color images available online at www.liebertpub.com/scd
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using conventional single-cell patch clamp or extracellular
field potentials using multicellular aggregates on multi-
electrode arrays [10]. That study used a single, unspecified
concentration of Nicorandil; so it is difficult to know exactly
how this relates to our data for this IKATP opener. We ob-
served a reduction in APD90 ranging from -15% to -22%
with the concentrations tested. Clinical dosage of Nicorandil
is as 40mg tablets that lead to a plasma Cmax of 300 ng/mL
(1,420 nM) 30min postadministration [36]. This is greater
than our highest concentration, consistent with the clinical
use of Nicorandil in treatment of ventricular tachycardia
[37], and so opens the possibility for evaluation in LQTS2
patients.
We also tested Minoxidil as an alternative modulator of
IKATP, where APD90 reduction associated well with con-
centration to a maximum of -17% at 1,000 nM. Minoxidil is
most commonly used as a topical treatment in hair products
for alopecia [38]. For internal use, the maximum permitted
dose is 100mg, but more commonly, the range is up to
40mg daily, where it acts as a powerful peripheral vasodi-
lator for treatment of hypertension [39], and is often used
with b-blockers [40]. This would make for a useful com-
bination in LQTS, where b-blockers control increase in
heart rate from the sympathetic nervous system stimulation,
while Minoxidil reduces the QT interval. Nevertheless,
Minoxidil would need to be used with some level of cau-
tion. In humans, one side effect is hypertrichosis (excessive
hair growth) by increasing expression of dermal papilla
markers [41], hence its common use in hair growth products
[42]. Also, studies in dogs have shown that cardiovascu-
lar toxicity occurs at *17 ng/mL [43], which equates to
80 nM. Therefore, it is promising that even at the lowest
concentration we tested (10 nM), highly significant reduc-
tions of *14% were seen for APD50 and APD90 in LQTS-
hiPSC-CMs.
Although the number of active IKr channels in LQTS2
patients is low, this current still remains a realistic target.
Previously, it was shown [18] that reducing expression of
the mutant KCNH2 transcript by allele-specific RNA inter-
ference in LQTS-hiPSC-CMs boosted the number of active
channels from 6% to 27%. This abolished arrhythmias and
reduced QT interval. However, while this approach worked
FIG. 4. Modulation of IKATP. LQTS2-hiPSC-CMs were treated with the IKATP enhancers, Minoxidil and Nicorandil. After
loading with the voltage-sensitive dye, FluoVolt, optical recordings made using the CellOPTIQ platform. Averaged traces
across the concentration range are shown in (A), while the derived percentage changes in APD50, APD90, and triangu-
larization are shown in (Bi; Minoxidil) and (Bii; Nicorandil). Data are mean – SEM with 40 replicates for BL (0) and 8
replicates for all other treatments; Dunnett’s test comparison to baseline (BL [0]); *P£ 0.05; **P£ 0.01; ***P £ 0.001;
****P£ 0.0001. Color images available online at www.liebertpub.com/scd
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well in vitro using siRNA or lentivirally delivered shRNAs,
the density and quantity of myocardium in the human heart
make this a challenging proposition in patients [44]. It is
possible that AAV or peptide delivery vehicles [45,46] may
overcome this issue.
In the immediate future, chemical modulation of IKr/
HERG is a more feasible route. Most drug interaction with
this channel induces prolongation of QT interval and is a
major risk factor that is considered in pharmaceutical drug
development [47]. Indeed, as part of an international ini-
tiative, termed CiPA (Comprehensive in Vitro Proar-
rhythmia Assay), healthy hiPSC-CMs are being evaluated
for their effectiveness as an early detection system for drug-
induced arrhythmias, including HERG blockers [48]. We
have previously shown [18] that in both healthy and LQTS2
hiPSC-CMs (KCNH2 G1681A), specific chemical blockade
of HERG with E4031 caused prolongation of field potential
duration and APD by up to 52% and 77%, respectively.
Arrhythmic-like events were detected in *30% of cases,
but only in the LQTS2-hiPSC-CMs. This confirms two key
points regarding LQTS2 CMs: (1) they show increased
susceptibility to drug-induced APD prolongation and ar-
rhythmias; and (2) the residual IKr current is still sufficient
to be a pharmacological target, prolonging in this case, but
prompting us to evaluate four compounds for their ability to
shorten QT interval.
Within this background context, direct chemical interac-
tion with HERG was investigated using Ginsenoside RG3
and NS1643. Derived as a pharmacologically active natural
constituent of plants of the genus Panax [49], RG3 exhibits
an antiapoptotic and anti-inflammatory effect shown to
improve cardiac function in rat models of myocardial in-
farction [50]. RG3 also interacts with IKr, at the channel
pore entryway to decelerate deactivation, and IKs, through
the KCNE1 subunit that co-assembles with KCNQ1 [51,52].
Only higher concentrations of RG3 were effective in re-
ducing APD50 and APD90 in LQTS-hiPSC-CMs, and there
was no effect on triangularization. This may be because
binding of RG3 to the serine residue in the pore of IKr is
weak. Also, the impact of RG3 on IKs activation is likely to
be minimal because this current is relatively small and there
has been controversy over whether it makes a meaningful
contribution to repolarization in hiPSC-CMs [53,54]. For
NS1643, we observed potent responses at all concentrations
tested, which was surprising. While others have shown ac-
celeration of repolarization in hiPSC-CMs, the concentra-
tions used have been substantially higher at up to 30 mM
[55] or >100mM [56] than those we used (10–1,000 nM).
The reasons for these differences are unclear, but may in-
clude mutation type (LQTS2 p.N996I vs. p.A561T) or the
method used to assess electrophysiology, wherein these ar-
ticles used multielectrode arrays to record extracellular field
potentials, while we used optical recording of changes in the
voltage-sensitive dye, FluoVolt. This also potentially high-
lights the challenge of cross-comparing data from different
platforms or cellular configurations. Indeed, simply plating
hiPSC-CMs at different densities appears to change APD
morphology and cardiac chamber specificity [57]. There-
fore, while it would be interesting to test the influence of
these drugs on the activity of specific ion channels, this
would necessitate switching from hiPSC-CMs in a contin-
uous monolayer using optical dyes on the CellOPTIQ to
isolated single cells using manual patch clamp, which could
confound data interpretation. Moreover, the high level of
heterogeneity associated with single CMs derived from
hiPSC-CM populations [58] means large numbers cells need
to be patched to reach statistical confidence.
Perhaps most interestingly, we were also able to use an
indirect approach to enhance IKr activity and hence reduce
QT interval. The PPARd pathway is pleotropic and associ-
ated with regulation of many processes, ranging from me-
tabolism, diabetes, and hypertension to cancer [35,59–62].
However, some literature, including in endothelial cell bi-
ology, suggests PPARd pathway agonists stimulate expres-
sion of YWHAE [63], whose gene product, 14-3-3 epsilon,
activates the HERG channel [21]. Therefore, we selected
two drugs that targeted the PPARd pathway. Telmisartan
was approved for use by the FDA in 2014 with potential
uses in fibrosis, type 2 diabetes, and hypertension. The
second compound was GW0742, which has a high speci-
ficity (EC50 of 1 nM) to PPARd. GW0742 has been used
experimentally to reduce lung inflammation in mice [64]
and has been shown to have cardioprotective effect against
ischemic injury in rats [65]. Since PPARd agonists have not
previously been evaluated for their ability to reduce QT
interval in LQTS, it was notable that at all concentrations
tested for GW0742 and nearly all for Telmisartan, signifi-
cant reductions in APD50, APD90, and triangularization
were observed. This suggests that PPARd agonists could
form a new class of drugs to treat LQTS2.
Nevertheless, further investigation will be required for
these PPARd agonists. They may also function through
other pathways and their dosage will be important. For
Telmisartan, we found highly significant benefit to APD
characteristics in LQTS2 hiPSC-CMs starting at 30 nM.
However, studies using doses of 1,000-fold higher (30 and
100 mM) in vivo in rats led to Na+ and Ca++ overload,
cardiac dysfunction, and CM death [66]. Also, Telmisartan
has an angiotensin receptor blocking activity and can
modulate PPARg [67]; so we cannot rule out activity
through these pathways. The same is true for GW0742,
which binds to PPARa or PPARg, although with an affinity
of at least 300-fold lower than to PPARd [68]. All three
PPAR isoforms are expressed in the heart [69]. Thus, it is
notable that both PPARd and PPARg have been shown
to associate with 14-3-3 epsilon [70], creating connectivity
to the HERG channel. Given the higher specificity of
GW0742 to PPARd and the additional PPARg:14-3-3 ep-
silon:HERG pathway, this may be the drug of choice for
further studies in LQTS.
In conclusion, we showed that six different direct or in-
direct channel modulators could reduce the APD charac-
teristics of LQTS2-hiPSC-CMs. The rank order (highest to
lowest) of these agents for change in APD90 at the minimum
concentration (10 nM) was Nicorandil (-21%) > GW0742
(-18%) > NS1643 (-13%) =Minoxidil (-13%) > Telmi-
sartan (-7%) > RG3 (+1%), while at the maximum con-
centration (1,000 nM), it was NS1643 (-20%) > GW0742
(-19%) =Telmisartan (-19%) > Minoxidil (-17%) > Ni-
corandil (-16%) > RG3 (-7%). This should be useful in-
formation when evaluating ion channel modulators in the
context of LQTS; the next steps will be to examine the
effect of these drugs in CMs from a wider range of hiPSC
lines carrying the same or different KCNH2 mutations.
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